SOUTH PLAINFIELD, N.J., Aug. 20 LAXAI, a Leading Contract Research Organization based in the US and India providing integrated services across the drug discovery and development spectrum today announced that it has appointed Naren Mallakunta as the Chief Executive Officer of the company.
Vamsi Maddipatla, Founder and President of LAXAI, welcomed the new appointment by saying, "Naren's knowledge of the industry, a continued track record of success and exceptional operational leadership make him the ideal choice to lead LAXAI as the CEO."
Naren Mallakunta said, "I am delighted to join a company which I strongly believe is critically positioned to offer unique value differentiators. I look forward to take the company forward to become a partner of choice to the Global Biopharmaceutical Industry in their drug discovery and development initiatives."
Prior to joining LAXAI, Naren was the Global Head of Business Development at GVK Biosciences. From its inception, Naren played a prominent role in building GVK Biosciences to become Asia's leading Contract Research Organization offering Drug Discovery and Development services. His experience in the industry includes structuring innovative business deals with Big Pharma and Biotech companies, some of which have been the biggest collaborations in the Contract Research Industry.
Naren has created and implemented successful developmental, managerial, and financial strategies for many business entities and his experience includes leadership positions in leading organizations.
LAXAI (www.laxai.com) provides services in Clinical Research, Medicinal Chemistry, Biology, Process R&D and Analytical Services, Strategic Resourcing and Training to the Biopharmaceutical and Agrochemical Companies. LAXAI offers a unique value proposition to clients in their drug discovery and development initiatives through innovative global partnership models.